Zacks Investment Research downgraded shares of ALPHATEC HLDGS (ATEC) from NEUTRAL to UNDERPERFORM on May 01, 2013, with a target price of $1.80.
Alphatec is a medical device company focused on the design, development, manufacturing and marketing of products for the surgical treatment of spine disorders. Alphatec's principal product offering is primarily focused on the estimated U.S. spine fusion market through its wholly-owned subsidiary, Alphatec Spine, Inc., and includes a variety of spinal implant products and systems comprised of components such as spine screws, spinal spacers, and plates that offer multiple solutions to address patients' needs. In addition to Alphatec's U.S. presence, it also participates in the Japanese spine fusion and orthopedic trauma markets through its subsidiary, Alphatec Pacific, Inc. Its mission is to be a value based leader in the spinal market by providing unmatched service to and taking scientific direction from our physician customers.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on ALPHATEC HLDGS (ATEC),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment